Shop Online : Advantage Multi Dog (Teal) 9.1 lbs - 20 lbs

Advantage Multi Dog (Teal) 9.1 lbs - 20 lbs

Advantage MultiTM for Dogs (10% imidacloprid + 2.5%

moxidectin) is a colorless to yellow ready-to-use solution

packaged in single dose applicator tubes for topical treatment

of dogs. Th e formulation and dosage schedule are designed

to provide a minimum of 4.5 mg/lb (10 mg/kg)

imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin based

on body weight.

Imidacloprid is a chloronicotinyl nitroguanidine

insecticide. Th e chemical name for imidacloprid is

1-[(6-Chloro-3-pyridinyl)methyl]-N-nitro-

2-imidazolidinimine. Moxidectin is a semisynthetic

macrocyclic lactone endectocide derived from the

actinomycete Streptomycetes cyaneogriseus noncyanogenus.

Th e chemical name for moxidectin is [6R, 23E, 25S(E)]-

5-O-Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-

6,28-epoxy-23-(methoxyimino) milbemycin B.

INDICATIONS:

Advantage Multi for Dogs is indicated for the prevention

of heartworm disease caused by Dirofi laria immitis.

Advantage Multi for Dogs kills adult fl eas and is

indicated for the treatment of fl ea infestations

(Ctenocephalides felis). Advantage Multi for Dogs is also

indicated for the treatment and control of the following

intestinal parasites:

CONTRAINDICATIONS:

Do not administer this product orally. (See WARNINGS.)

Do not use this product (containing 2.5% moxidectin) on cats.

WARNINGS

For the fi rst 30 minutes aft er application:

Ensure that dogs cannot lick the product from

application sites on themselves or other

treated dogs, and

Separate treated dogs from one another and from

other pets to reduce the risk of accidental ingestion.

Ingestion of this product by dogs may cause serious

adverse reactions including depression,

salivation, dilated pupils, incoordination,

panting, and generalized muscle tremors.

In avermectin sensitive dogs,a the signs may be

more severe and may include coma and death.b

a Some dogs are more sensitive to avermectins due to a mutation in

the MDR1 gene. Dogs with this mutation may develop signs of severe

avermectin toxicity if they ingest this product. Th e most common

breeds associated with this mutation include Collies and Collie crosses.

b Although there is no specifi c antagonist for avermectin toxicity, even

severely aff ected dogs have completely recovered from avermectin

toxicity with intensive veterinary supportive care.

HUMAN WARNINGS:

Not for human use. Keep out of the reach of children.

Children should not come in contact with

application sites for two (2) hours aft er application.

Causes eye irritation. Harmful if swallowed. Do not get in

eyes or on clothing. Avoid contact with skin. Wash hands

thoroughly with soap and warm water aft er handling.

If contact with eyes occurs hold eyelids open and fl ush with

copious amounts of water for 15 minutes. If eye irritation

develops or persists, contact a physician. If swallowed, call

poison control center or physician immediately for treatment

advice. Have person sip a glass of water if able to swallow.

Do not induce vomiting unless told to do so by the poison

control center or physician. People with known

hypersensitivity to benzyl alcohol, moxidectin, or

imidacloprid should administer the product with caution.

In case of allergic reaction, contact a physician. If contact with

skin or clothing occurs, take off contaminated clothing. Wash

skin immediately with plenty of soap and water. Call a poison

control center or physician for treatment advice.

Th e Material Safety Data Sheet (MSDS) provides additional

occupational safety information.

For a copy of the Material Safety Data Sheet (MSDS) or to

report adverse reactions call Bayer Veterinary Services

at 1-800-422-9874. For consumer questions call

1-800-255-6826.

PRECAUTIONS:

Do not dispense dose applicator tubes without complete

safety and administration information.

Use with caution in sick, debilitated, or underweight animals.

Th e safety of Advantage Multi for Dogs has not been

established in breeding, pregnant, or lactating dogs. Th e safe

use of Advantage Multi for Dogs has not been established

in puppies and dogs less than 7 weeks of age or less than 3 lbs.

body weight.

Prior to administration of Advantage Multi for Dogs,

dogs should be tested for existing heartworm infection. At the

discretion of the veterinarian, infected dogs should be treated

with an adulticide to remove adult heartworms. Advantage

Multi for Dogs is not eff ective against adult D. immitis.

While the number of circulating microfi lariae may decrease

following treatment, Advantage Multi for Dogs is not

eff ective for microfi lariae clearance. (See ANIMAL SAFETY

– Safety Study in Heartworm-Positive Dogs.)

ADVERSE REACTIONS:

Field Studies: Following treatment with Advantage Multi

for Dogs or an active control, dog owners reported the

following post-treatment reactions:

During a fi eld study using 61 dogs with pre-existing fl ea

allergy dermatitis, one (1.6%) dog experienced localized

pruritus immediately aft er imidacloprid application, and

one investigator noted hyperkeratosis at the application site

of one dog (1.6%).

Laboratory Eff ectiveness Studies: One dog in a laboratory

eff ectiveness study experienced weakness, depression, and

unsteadiness between 6 and 9 days aft er application with

Advantage Multi for Dogs. Th e signs resolved without

intervention by day 10 post-application. Th e signs in this dog

may have been related to peak serum levels of moxidectin,

which vary between dogs, and occur between 1 and 21 days

aft er application of Advantage Multi for Dogs.

Th e following clinical observations also occurred in

laboratory eff ectiveness studies following application with

Advantage Multi for Dogs and may be directly attributed

to the drug or may be secondary to the intestinal parasite

burden or other underlying conditions in the dogs:

diarrhea, bloody stools, vomiting, anorexia, lethargy,

coughing, ocular discharge and nasal discharge.

Observations at the application sites included damp, stiff

or greasy hair, the appearance of a white deposit on the

hair, and mild erythema, which resolved without treatment

within 2 to 48 hours.

Intestinal Parasite

Intestinal Stage

Adult Immature

Adult

Fourth Stage

Larvae

Hookworm

Species

Ancylostoma caninum X X X

Uncinaria stenocephala X X X

Roundworm

Species

Toxocara canis X X

Toxascaris leonina X

Whipworm Trichuris vulpis X

Topical Solution

OBSERVATION Advantage Multi n=128 Active Control n=68

Pruritus 19 dogs (14.8%) 7 dogs (10.3%)

Residue 9 dogs (7.0%) 5 dogs (7.4%)

Medicinal Odor 5 dogs (3.9%) None observed

Lethargy 1 dog (0.8%) 1 dog (1.5%)

Inappetence 1 dog (0.8%) 1 dog (1.5%)

Hyperactivity 1 dog (0.8%) None observed

08944698

08944698

Foreign Market Experience: Because the following events

were reported voluntarily during post-approval use of the

product in foreign markets, it is not always possible to

reliably establish a causal relationship to drug exposure.

Th e following adverse events were reported in humans: eye

irritation, allergic reactions, skin irritation, skin tingling,

sore throat, and chemical odor. Adverse events reported in

dogs topically treated with imidacloprid + moxidectin for

dogs included: vomiting, diarrhea, bloody diarrhea,

salivation, poor appetite, lethargy, weakness, restlessness,

agitation, disorientation, ataxia, muscle tremors, seizures,

panting, labored breathing, acute pulmonary edema, hives,

rash, swollen face and ears, pruritus, erythema, alopecia,

hot spots, local discomfort, and discoloration of the hair

at the application site. Accidental oral ingestion in dogs

caused salivation, vomiting, muscle tremor, seizures,

mydriasis, ataxia, lethargy, disorientation, agitation, and

poor appetite. Adverse reactions reported in cats treated

topically with imidacloprid + moxidectin for dogs included

application site and skin reactions, vomiting, lethargy,

agitation, and neurologic signs.

To report a suspected adverse reaction, call 1-800-422-9874.

DOSAGE AND ADMINISTRATION:

Th e recommended minimum dose is 4.5 mg/lb (10 mg/kg)

imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a

month, by topical administration.

Do not apply to irritated skin.

1. Remove one dose applicator tube (tube) from the package.

As specifi ed in the following table, administer the entire

contents of the Advantage MultiTM for Dogs tube that

correctly corresponds with the body weight of the dog.

*Dogs over 88 lbs. should be treated with the appropriate combination

of Advantage Multi for Dogs tubes.

2. While holding the tube in an upright position, remove the

cap from the tube.

3. Turn the cap over and push the other end of cap onto the tip

of the tube.

4. Twist the cap to break the seal and then remove cap from

the tube.

5. Th e dog should be standing for application. Part the hair on

the back of the dog between the shoulder blades until the

skin is visible. For dogs weighing 20 lbs. or less, place the tip

of the tube on the skin and apply the entire contents directly

on the exposed skin at one spot between the shoulder blades.

For dogs weighing more than 20 lbs., place the tip of the

tube on the skin and apply the entire contents directly on the

exposed skin at 3 or 4 spots on the top of the backline from

the base of the neck to the upper back in an area inaccessible

to licking. Do not apply an amount of solution at any one

location that could run off the side of the dog.

Do not let this product get in your dog’s mouth or eyes.

Do not allow the dog to lick any of the application sites for

30 minutes. In households with multiple pets, keep each

treated dog separated from other treated dogs and other pets

for 30 minutes aft er application to prevent licking the

application sites. (See WARNINGS.)

Stiff hair, a damp appearance of the hair, pink skin, or a slight

powdery residue may be observed at the application site on

some animals. Th is is temporary and does not aff ect the safety

and eff ectiveness of the product.

Shampooing 90 minutes aft er treatment does not reduce the

eff ectiveness of Advantage Multi for Dogs in the prevention

of heartworm disease.

Shampooing or water immersion 4 days aft er treatment will not

reduce the eff ectiveness of Advantage Multi for Dogs in the

treatment of fl ea infestations. However, shampooing as oft en

as once weekly may reduce the eff ectiveness of the product

against fl eas.

Heartworm Prevention: For prevention of heartworm

disease, Advantage Multi for Dogs should be administered

at one-month intervals. Advantage Multi for Dogs may be

administered year-round or at a minimum should start one

month before the fi rst expected exposure to mosquitoes and

should continue at monthly intervals until one month aft er the

last exposure to mosquitoes. If a dose is missed and a 30-day

interval between doses is exceeded, administer Advantage

Multi for Dogs immediately and resume the monthly dosing

schedule. When replacing another heartworm preventative

product in a heartworm prevention program, the fi rst

treatment with Advantage Multi for Dogs should be given

within one month of the last dose of the former medication.

Flea Treatment: For the treatment of fl ea infestations,

Advantage Multi for Dogs should be administered at

one-month intervals. If the dog is already infested with

fl eas when the fi rst dose of Advantage Multi for Dogs is

administered, adult fl eas on the dog will be killed. However,

reinfestation from the emergence of pre-existing pupae in the

environment may continue to occur for six weeks or longer

aft er treatment is initiated.

Dogs treated with imidacloprid, including those with pre-existing

fl ea allergy dermatitis have shown clinical improvement as a

direct result of elimination of fl eas from the dog.

Treatment and Control of Intestinal Nematode Infections:

For the treatment and control of intestinal hookworm

infections caused by Ancylostoma caninum and Uncinaria

stenocephala (adults, immature adults and fourth stage larvae)

and roundworm infections caused by Toxocara canis (adults